Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629 is registered in ClinicalTrials.gov with Intellia Therapeutics as lead sponsor.

NCT NCT06128629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06128629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Lead sponsor
Intellia Therapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
December 13, 2023
Completion date
April 30, 2028
Enrollment
1,200 (estimated)
Sites
132

Conditions

As the registry lists them; a condition with its own page is linked.

transthyretin amyloidosis (attr) with cardiomyopathy